The Philips BlueControl wearable light therapy device has been approved by the Food and Drug Administration (FDA) to treat mild psoriasis.

The device straps to affected psoriasis areas (ie, arms, legs, elbows, knees) and emits a UV-free blue LED light. It is designated a Class II prescription medical device.

A clinical trial (Pfaff S et al. 2015) of 47 individuals with mild psoriasis found significant improvement in change from baseline of Local Psoriasis Severity Index in patients receiving UV-free blue light home treatment.

The Philips BlueControl has been available in Europe since 2015. “We are pleased that we can now start marketing this innovative home treatment solution for psoriasis to dermatologists in the U.S.” said David Aubert, General Manager of Philips’ Light & Health business. 

Related Articles

The company indicated that they will start to engage with dermatologists and patient support groups for a planned commercial U.S. launch in early 2018.

For more information visit